The inhibition of Ca2+-dependent phosphorylation of cardiac proteins by palmitoylcarnitine may be related to the accumulation of this fatty acid intermediate during myocardial ischemia.
Answers are grounded in this paper and cite their sources.
May link palmitoylcarnitine to ischemic kinase inhibition in animal tissue; leaves open human relevance and therapeutic implications.
At least two substrate proteins for phospholipid-sensitive Ca2+-dependent protein kinase and at least six substrates for calmodulin-sensitive Ca2+-dependent protein kinase were identified in the cytosol of the guinea pig heart. In the particulate subfractions enriched in nuclei, mitochondria, microsome, or plasma membrane, no substrates for the phospholipid-sensitive enzyme were demonstrated but at least four substrates for the calmodulin-sensitive enzyme were identified. The present studies suggest that phospholipid, acting independently of calmodulin, is likely to be involved in the regulation of Ca2+-dependent protein phosphorylation in the heart. Phosphorylation of endogenous substrates for the two enzyme systems was effectively inhibited by palmitoylcarnitine. When histone was used as exogenous substrate, the carnitine ester inhibited the cardiac phospholipid-sensitive Ca2+-dependent protein kinase but not the cardiac cyclic AMP-dependent and cyclic GMP-dependent protein kinases. It is suggested that inhibition of the Ca2+-dependent phosphorylation of cardiac proteins, regulated by either phospholipid or calmodulin, is probably related in part to the great increase in this fatty acid metabolic intermediate in the ischemic heart.
No takes yet. Share an insight, caveat, or question.
Katoh et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: